AI-generated analysis. Always verify with the original filing.
Spruce Biosciences entered into a new Open Market Sale Agreement with Jefferies LLC to sell up to the Maximum Program Amount of common stock at-the-market, replacing the prior 2022 agreement; announced full year 2025 financial results with net loss of $39.0 million; and appointed Corwin Dale Hooks as Chief Commercial Officer effective March 9, 2026 with $480,000 base salary and 11,000 RSU award.
Event Type
Disclosure
Mandatory
Variant
8-K
Entry into a Material Definitive Agreement. On March 9, 2026, Spruce Biosciences, Inc. (the “Company”) entered into an Open Market Sale Agreement SM (the “Sales
. Item 2.02 Results of Operations and Financial Condition. On March 9, 2026, the Company issued a press release announcing its financial results for the full ye
and Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), and shall not
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment o
Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 1.1 Open Market Sales Agreement SM , dated March 9, 2026, by and between Spruce Bios
| Metric | Value | Basis |
|---|---|---|
| Net Loss | $39.0K | GAAP |
| Research and Development Expenses | $19.5K | GAAP |
| General and Administrative Expenses | $17.0K | GAAP |
| Total Operating Expenses | $36.5K | GAAP |
Corwin Dale Hooks
Effective: 2026-03-09
N/A
Material Agreement